ATLANTA, June 24, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of FINTEPLA® (fenfluramine) in reducing the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) among patients with developmental and epileptic encephalopathies (DEEs). This analysis highlighted a significant reduction in both GTCS and TCS across various DEEs adding to the already established data from the FINTEPLA clinical trial program.2
ATLANTA, May 23, 2024 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, in the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).1 This article represents the primary publication of BIMZELX data from the two pivotal Phase 3 HS studies. HS is one of the most burdensome, chronic, systemic, inflammatory skin diseases that can have a profound impact on patients' health-related quality of life.2,3,4
BIMZELX Phase 3 Showed Improvements in Skin Pain and Draining Tunnel Count
After busy 2023, UCB expects approval spree to keep rolling
FDA Issues Form 483 to UCB Farchim SA
ATLANTA, Oct. 4, 2023 /PRNewswire/ -- The Child Neurology Society Meeting, a prominent event in the field of pediatric neurology, is set to showcase cutting-edge research and developments in child neurology. As part of this conference, UCB will present two late-breaking posters that shed light on the care and management of Dravet syndrome.
After a manufacturing-related complete response letter held up the U.S. launch of UCB’s psoriasis med bimekizumab last May, the FDA has officially closed out its inspection of the company's plant in Belgium.
Lundbeck CEO Deborah Dunsire is stepping down on a high note in the neuroscience company’s history.
Ariceum Therapeutics has entered into an exclusive strategic research collaboration agreement with UCB to discover and develop new systemic targeted radiopharmaceuticals to treat immune-related diseases and solid tumours.